Clinical Trials ·
The SYNERGY-OUTCOMES study aims to evaluate the efficacy of retatrutide in preventing major adverse liver outcomes in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). This clinical trial will assess whether retatrutide, compared to tirzepatide and placebo, can effectively mitigate the risks associated with MASLD in a high-risk population.
What this source covers
The SYNERGY-OUTCOMES study, registered under ClinicalTrials.gov (NCT07165028), is designed to investigate the potential of retatrutide and tirzepatide in preventing major adverse liver outcomes (MALO) in adults diagnosed with MASLD. The study will enroll approximately 4,500 participants who will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo. The trial is expected to last around 224 weeks, during which participants will undergo regular health monitoring and assessments of liver function.
Why it matters for Retatrutide research
This study is significant for retatrutide research as it explores the drug's potential role in addressing a critical health issue—MALO in patients with MASLD. Given the rising prevalence of metabolic disorders and associated liver diseases, understanding the efficacy of retatrutide in this context could provide valuable insights into its therapeutic applications. The findings may also contribute to the broader understanding of how GLP-1 receptor agonists like retatrutide can influence liver health.
Key findings or claims
- The SYNERGY-OUTCOMES study will assess the efficacy of retatrutide in preventing MALO in high-risk MASLD patients.
- Participants will be randomly assigned to receive either retatrutide, tirzepatide, or placebo.
- The trial plans to enroll approximately 4,500 adults and will run for about 224 weeks.
- Regular monitoring will occur with up to 30 clinic visits to assess health and liver function.
- Eligible participants may join an optional 2-year extension study post-trial.
Context and prior work
Retatrutide is part of a class of medications that includes GLP-1 and GIP receptor agonists, which have shown promise in managing metabolic disorders. Previous studies have indicated that such agents can lead to improvements in metabolic health, weight reduction, and possibly liver function. The SYNERGY-OUTCOMES study builds on this foundation by specifically targeting the prevention of liver complications in a population at high risk for MALO, thereby contributing to the growing body of literature on the metabolic benefits of these therapies.
Practical takeaways for researchers
Researchers should consider the implications of the SYNERGY-OUTCOMES study for future investigations into retatrutide and its effects on liver health. The trial's design, which includes a large participant pool and extended monitoring, may yield robust data on the long-term effects of retatrutide in patients with MASLD. Additionally, the optional extension study could provide further insights into the drug's efficacy beyond the initial trial period.
FAQ
What is the primary goal of the SYNERGY-OUTCOMES study?
The primary goal is to determine whether retatrutide and tirzepatide can prevent major adverse liver outcomes in adults with MASLD.
How long will the SYNERGY-OUTCOMES study last?
The study is expected to run for approximately 224 weeks.
Can participants receive retatrutide after the main study?
Yes, eligible participants may join an optional 2-year extension study where they will receive either retatrutide or tirzepatide.
Source: ClinicalTrials.gov · NCT07165028 · published 2026-04-17.